Trinity Biotech Secures Major Regulatory Approval for Offshored and Outsourced Manufacturing of Its Market Leading Uni-Gold Rapid HIV Test, Further Accelerating Financial Performance Transformation

Core Insights - Trinity Biotech has received WHO approval for offshored and outsourced upstream manufacturing of its Uni-Gold™ HIV rapid test, marking a significant milestone in its transformation plan aimed at sustainable profitability [1][7] - The transition to an outsourced manufacturing model is expected to enhance gross margins, EBITDA, and cash flow generation, while maintaining product integrity and regulatory compliance [2][5] Company Strategy - The initiative is part of a complex project developed over two years, showcasing the leadership's capability to execute strategic business transformations for long-term capital value [3] - The company aims to streamline operations, reduce fixed costs, and focus on innovation and market expansion through strategic partnerships with world-class manufacturing providers [4][5] Financial Impact - The expected improvements in gross margin, EBITDA, and cash flow generation are central to the company's profitability-focused transformation strategy [5][7]